SHANTI THERAPEUTICS

SOLVING CHRONIC PAIN WITH THERAPEUTIC GRADE PSYCHEDELIC SOLUTIONS

Solving chronic pain with therapeutic grade psychedelic solutions

Our mastery of biotechnology is pointing the way toward breakthrough therapies for chronic pain and depression.

WHAT WE DO

We are transforming the treatment of chronic pain, psychiatric ailments and depression by pioneering trials of fixed-dose drugs, combining psilocybin, ketamine, and MDMA, embracing the endless possibilities of micro-dosing.

KEY ACHIEVEMENTS AND ASSETS

Shanti holds an import license and license to supply schedule 8 poisons (MDMA and Psilocybin)​

Established Telehealth clinic for prescribing Psychedelic drugs​

A strong executive team is in place​

A University-led clinical trial with the Swinburne Institute of Technology is ready for ethics approval​

Opening the first of its kind telehealth psychedelic clinic for prescribing psychedelic drugs

Prescribing psilocybin, ketamine and MDMA for treating a variety of psychiatric ailments. This will allow national patient access via a medical practitioner using a low-cost online model.

Chronic pain market size and growth rate​

In 2015 to 2018 ​in the United States, 10.7% of adults used prescription medications in the ​ past 30 days.2

In 2015 to 2018 ​ 5.7% of U.S adults used one or more prescription opioids.​

3.24 million Australians were living with chronic pain in 2018.3

The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7 billion in 2030.4

2. CDC / NCHS data brief #369 June 2020​
3. The Cost of Pain in Australia – Deloitte Access Economics March 2019​
4. Global Chronic Pain Treatment Market Analysis and Growth Forecast Report 2020 – 2030 ResearchAndMarkets.com

Australasian chronic pain market size & growth rate

It is estimated that one in five Australians experience chronic pain.

BEACH¹ data collected in 2013 indicated 19.2% of patients attending General Practices report chronic pain. Of those 37.7% were graded III / IV (highest pain level).

Medication was used for pain management by 86.1% of patients.

One third of patients were taking Opioids (typically for the higher pain grades).

THE INNOVATIVE TEAM

Our team expands the possibilities of science to create transformative therapies for patients with chronic pain.

Shanti is building a team of experts in the fields of novel drugs CDB MDMA cognitive neuroscience Cannabinoids using the micro dosing delivery method for pain management with expertise in Anaesthesiologist, Neuroscientist, Regulatory Affairs.

Scientific advisors

Dr Sarah Catchlove

Advisor

Prof Con Stough

Chief Scientific Officer

Medical advisory board

A/Prof Michael Keane

Advisor

Dr John Crock

Advisor

THE INNOVATIVE TEAM

Our team expands the possibilities of science to create transformative therapies for patients with chronic pain, Psychiatric ailments, and depression—experts in novel drugs Anaesthesiologist, Neuroscientist, Regulatory Affairs cognitive neuroscience, and Cannabinoids.

Shanti Therapeutics – why invest​

First mover in the Australian psychedelic space.​

Experienced executive team with significant learnings from the cannabis industry.​

Strong medical, clinic and research skills​

All licenses for import, storage and supplying psychedelics to patients are in place​

Psychedelic prescribing clinic established in Australia for Special Access Scheme prescribing​